Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report's newsroom for a candid, insider's perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.
Episode 48: Approved 340B Rebate Plans, PhRMA's New CEO, Child Site Litigation and State Updates
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including the newly-approved manufacturer 340B rebate pilot plans. They also discuss a new multi-organization community health center letter to Congressional leadership shared exclusively with 340B Report; the Pharmaceutical Research and Manufacturers of America's (PhRMA) new CEO; a 340B child site litigation update; and two 340B developments in the states.
Key Topics Covered:
HRSA's Rebate Pilot Plans
Will breaks down the Health Resources and Services Administration's (HRSA) recently approved manufacturer 340B rebate pilot plans. He also explains why two drugmakers may have chosen not to include their eligible drugs in the pilot. Meanwhile, Luke details a new letter from more than 50 community health center associations representing over 1,500 health centers asking certain U.S. House leaders to hold a hearing on the "impending implementation" of the 340B rebate model pilot.
PhRMA's New Leader
Luke discusses PhRMA's new President and CEO Eric Cantor, who formerly served in Congress as the House Majority Leader for Republicans from 2011 to 2014. Cantor was not active in 340B policy during his time on the Hill, but usually backed the drug industry in other policy areas. Ted provides his take on PhRMA's choice during the current political environment.
340B Child Site Ruling Appeal
Will explains the latest in HRSA's appeal of a Washington, D.C., federal court ruling that struck down the agency's 340B hospital offsite clinic registration policy. He breaks down why the ruling was a victory for hospitals, as well as why both HRSA and PhRMA are arguing the ruling should be overturned. Will also discusses an amicus brief from four manufacturers taking a different approach.
State 340B Updates
Luke breaks down two new similar bills introduced in each chamber of the Pennsylvania legislature. Both bills would prohibit manufacturers from restricting delivery of 340B drugs to covered entities or their contract pharmacies and ban 340B claims data requirements not required under federal law, among other changes. Will then breaks down an Arkansas' federal judge's ruling in favor of that state's 340B contract pharmacy access law, and the history of that state's litigation.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, RxParadigm (https://rxparadigm.com/). RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs and effective 340B program administration. We are very grateful to RxParadigm for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
14 Sept 2026
Episode 47: 340B to CMS? Possible 340B Hospital Cuts, Legal Updates and 340B Report's New Resource
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including: 340B Report's scoop that the Trump administration is reportedly planning to shift 340B oversight to the U.S. Centers for Medicare and Medicaid Services (CMS); reactions to a proposal to slash Medicare Part B reimbursement for 340B hospitals; two major 340B legal developments; and a recap of 340B Report's latest webinar.
Key Topics Covered:
Shifting 340B Oversight?
Will details 340B Report's recent news alert reporting that the Trump administration plans to shift 340B oversight from its longtime home at the Health Resources and Services Administration (HRSA) to CMS this month. HRSA and CMS have not confirmed the report, which was based on a conversation with a source familiar with the plans. Will also explains why many 340B providers are concerned with the potential shift.
Competing Takes on 340B Hospital Cuts
Shannon discusses concerns 340B hospitals and New York congressional Republicans raised in public comments on CMS' proposed 2027 Hospital Outpatient Prospective Payment System rule, which would cut Medicare Part B reimbursement for 340B-acquired outpatient drugs. Meanwhile, Luke and Ted note that other stakeholders—including a private oncology practice group and a trade association of for-profit hospitals—have supported the move.
340B in the Courts
Will breaks down two recent federal district court rulings dismissing manufacturer challenges to Colorado's 340B access law. He also shares an update on Sanofi's ongoing lawsuit against HRSA seeking providers' pharmacy services agreements. Will notes that HRSA has recently contacted multiple providers about these contracts, which Sanofi argues could reveal that covered entities transfer the title of 340B drugs to contract pharmacies in violation of the 340B statute.
340B Report's New Explainer
Luke gives kudos to the editorial team on their recent webinar covering the 340B program's history and major tension points for both subscribers and nonsubscribers. He also discusses 340B Report's new explainer, which breaks down 340B program history, operations, oversight, key tension points and other important details.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, PharmaForce (https://www.thepharmaforce.com/). PharmaForce is the only third-party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We are very grateful to PharmaForce for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
28 Aug 2026
Episode 46: Patient Definition Case Heats Up, PhRMA's Leadership Hunt and a New 340B Hospital Bill
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including: a key development in AbbVie's lawsuit challenging the Health Resources and Services Administration's (HRSA) 340B patient definition; potential candidates to become the next leader of an influential drug industry trade group; a new federal bill that would temporarily maintain 340B hospital eligibility; and the latest on the 340B rebate model pilot.
Key Topics Covered:
Providers Have a Say in Patient Definition Suit
Will breaks down a Washington, D.C. federal judge's recent ruling allowing three national 340B provider groups to intervene inAbbVie's lawsuit challenging HRSA's 340B patient definition. He explains that, as intervenors, the groups will defend HRSA's definition and can participate in briefings and hearings, and potentially appeal any decisions. Will notes that the outcome of the case could have major 340B program implications, and discusses how it relates to a prior provider lawsuit involving HRSA's patient definition.
Who Will Lead PhRMA?
Shannon discusses the former Republican policymakers Pharmaceutical Research and Manufacturers of America (PhRMA) is reportedly considering to replace its outgoing President and CEO Stephen Ubl. She notes that they include: former U.S. Reps. Greg Walden (R-Ore.), who previously chaired the House Energy and Commerce Committee, and Eric Cantor (R-Va.), former Louisiana Gov. Bobby Jindal (R) and former Centers for Medicare and Medicaid Services (CMS) Administrator Seema Verma. She and Ted reflect on the candidates' past records on 340B issues, while Ted offers some historical context on previous lawmakers that the big drug industry trade groups have selected to lead their organizations. He also speculates on what PhRMA might do this time.
New 340B Hospital Bill
Luke details a new bill aimed at addressing hospital concerns that recent Medicaid cuts in the "big beautiful bill" could cause some hospitals to lose 340B eligibility. U.S. Rep. Hillary Scholten (D-Mich.) introduced the bill, which would temporarily maintain 340B eligibility for certain hospitals if their disproportionate share hospital (DSH) adjustment percentage falls below the required threshold.
Latest on the Rebate Model
Will discusses the latest in HRSA's revised 340B rebate model pilot set to take effect on Jan. 1, 2027. He notes that drugmaker rebate plan applications were due Aug. 24, and that HRSA said it plans to announce approvals on Sept. 24. Will also speculates that any provider litigation challenging the rebate pilot is likely months away, as last year's successful hospital lawsuit was not filed until December 2025.
Subscribe & Stay Updated
How to Follow Us and Learn More About This Episode's Sponsor
Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.
This episode is brought to you by one of our great Ultra Diamond sponsors, NuvemRx. NuvemRx empowers covered entities to turn 340B from a compliance burden into a strategic asset with a full suite of TPA, in-house pharmacy and referral solutions. Learn more at www.nuvemrx.com. We are very grateful to NuvemRx for its sponsorship.
Subscribe to 340B Report with a Special Discount
We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
4 ratings
Spotify
5.0 / 5
7 ratings
Podcast Authority Score: 33 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
53
Social presence
0
YouTube
0
Engagement
32
Contact Inside 340B Report
Guest appearances
Does not typically book guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
